Ultra Nasdaq Biotechnology 2X ETF (BIB)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

macrossluvsrobotech
macrossluvsrobotech Sep. 11 at 4:31 PM
$LXRX Just in 1bil from Novo, puts our share value at: 2.47 ... our cash is .30 cent a share. Meaning, FAIR MARKET VALUE JUST ON NOVO AND CASH? 2.77 a share. NOT COUNTING THE SUBMITTAL=AND EVERYTHING ELSE= I SAID .80 CENTS IN PRIOR POSTS IN INCREMENTAL ROYALTIES... ON TOP OF THIS OBVIOUS VALUATION...I SHOULD HAVE BEEN CLEARER. 445 mil shares divided by 1 bil = 2.47 a share. PLUS .30 cents from our cash. ALONE put's us at 2.77 a share. NOT COUNTING THE MINIMUM .80 CENT ROYALTY MINIMUM VALUE PER SHARE IN THE FUTURE FROM REVENUE SHARE SALES. WHICH EASILY PUTS US AT 3.05 SHARE. $NVO $VTRS $BIB $SPY = ( AI SOFTWARE LAYER FACTOR FOR GENOME 5,000 VAULT, WITH OTHER INDICATIONS AND ONCOLOGY AS AN EXAMPLE, AND MENTIONED )
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 11 at 4:04 PM
$LXRX — count the VALUE/estate, not just the 'ticker'. Novo LX9851 (oral obesity / fat-metabolism pill): up to $1B headline. $75M already in. Rest = milestones (goal payments) + royalties (sales cut). Easy minimum, floor value per share ≈ $0.80/sh. Zynquista T1D (type 1 diabetes): ~1M US adults. No approved *oral* add-on to minimize need 4 daily painful insulin jab. FIRST OF ITS KIND- IN THE U.S. Q4 FDA file (Oct–Dec). Efficacy accepted!!!!!!!!. Gate was DKA (dangerous acid buildup). STENO-1 (Denmark safety study) was that gate. Minimum value in sales per share: ≈ $2.20/sh. SONATA + AAK1 appx minimum value per share ≈ $1.45/sh. SONATA = P3 (late trial) in HCM (thick stiff heart), Q1’27. Camzyos ( another similar brand, inferior ) already banks ~$1B+/yr; no nHCM . AAK1 = pilavapadin, non-opioid for DPNP (diabetic nerve pain). P3 = partner’s check, but could be 1.80-3.80 minimum value per share in royalties. Add: ~$6.80–8.80+ vs ~$2. Not a promise. A ledger. $NVO $VTRS $BIB $SPY
0 · Reply
SniperPro
SniperPro Sep. 10 at 11:30 AM
$LXRX $NVO $VTRS $BIB $SPY 🤑 Amazing presentation!!! 🤑 🚀💪💰 IF YOU’RE LOOKING TO PARTNER, THIS IS ONE TO WATCH. 🤝🔥
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 11:03 PM
$LXRX Citi Webcast Takeaways — Disciplined Execution Over Hype 🧬📊 1. T1D NDA (Zynquista): Targeted for Q4 submission. Exton confirmed the Steno-1 exposure hurdle was hit in late August: "Data is done... preparing it and getting ready to submit." DKA rate came in lower than inTandem and similar to standard of care, meeting FDA's stated risk-benefit criteria. 2. HCM (North Star) Q1 '27: SONATA-HCM over-enrolled past 500 patients across 130+ sites. Broad EF range plus a unique background CMI cohort. Management framed a +3-pt placebo-adjusted KCCQ delta as a commercial home run. 3. Capital Discipline on Pain: Pilavapadin (LX9211) won’t drain cash in a self-funded Phase 3. Presenting new cardiometabolic preclinical data later this year to bundle into an expanded partnership package. 4. Genome 5000 + AI: Evaluating an AI query layer over 30 years of proprietary knockout data (origin of Sota, LX9851, LX9211) to explore untouched oncology/immuno. Pure optionality. $NVO $VTRS $BIB $SPY
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 11:00 PM
$LXRX Citi Fireside Breakdown: Big Catalysts & Major AI Discovery Reveal 🧬🚀 1. T1D NDA Locked for Q4: CEO Exton confirmed the Steno-1 exposure hurdle was officially achieved in late August. "Data is done. Now we just are in the throes of preparing it and getting ready to submit." DKA rate matched standard of care and was below in Tandem. FDA green light ready! 2. HCM (North Star) Q1 '27: SONATA-HCM over-enrolled 500+ pts across 20 countries. Covers broad EF range + first-ever CMI background cohort. Management framed a 3-pt KCCQ delta as a commercial "home run." 3. AAK1 Expansion: Pilavapadin (LX9211) won’t drain cash. Presenting new preclinical data in cardiometabolic indications later this year to maximize partnership value. 4. Genome 5000 + AI: Revealing an AI query engine overlaid on 30 yrs of proprietary knockout mouse data (source of Sota, LX9851, LX9211) to unlock untapped oncology & immunology assets! Execution mode across all fronts. $NVO $VTRS $BIB $LLY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 9:38 PM
$LXRX First Conference of Operation Conference Blitzkrieg ; ) , 3 in a row, or go home!!, prior to Inpefa submission: Ready to be listened to, here, for all interested parties: 39 minutes long. CEO's own words: 'we are very soon to submit INPEFA', ; ) New Data, New Admin, New Regime. It's 2026. Not 2019. This webcast can now be discussed on our board, =NOTE THIS IS THE EXACT SAME DAY THEY participated via Lexicon’s Attendees: The individuals representing Lexicon in the audience and at the networking tables are: Lexicon’s internal Patient Advocacy & Public Policy / Government Affairs leads. While CEO was today at the event link below CITI Back to School Confernece, which you can listen to now below. Retained D.C. healthcare lobbying and policy consultants who manage Lexicon's Capitol Hill outreach. Washington/Hill Presentation will be discussed here- should be very interesting ) https://investors.lexpharma.com/news-events/events $NVO $VTRS $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 7:46 PM
$LXRX Current Price vs. Fair Value: Old Fears vs. 2026 Facts 🧬📊 At ~$2.14, backing out ~$0.30 net cash means the market is already pricing ~$1.84 for the science. The ~$5.40 fair value case doesn't deny this. It argues that $1.84 is being weighed down by old 2019 FDA rejection fears, ignoring the updated 2026 clinical record: • Novo Nordisk ($NVO): Already paid $75M cash. Valuing realistic future milestones and royalties adds ~$0.80/sh. • Type 1 Diabetes (Zynquista): ~$2.25/sh. STENO1 cleared key safety hurdles ahead of the Q4 FDA filing (and the molecule is already FDA-approved as INPEFA). • Core Pipeline: ~$1.45/sh. A Phase 3 heart disease trial fully enrolled (Q1 '27 readout) plus a Phase 3-ready non-opioid pain drug. The Math: $0.30 cash + $0.80 Novo + $2.25 T1D + $1.45 pipeline = ~$4.80–$5.80 baseline fair value (up to $7.20+ as T1D approval odds climb). $2.14 is a seller who cannot wait. $5.40 is a buyer who can. Different patience, different value. $VTRS $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 3:11 AM
$LXRX The Longevity Supercycle: Why ONE Landmark Nature Study Changes Everything 🧬📈 The scientific consensus just shifted. A foundational September 2026 study published in *Nature*—amplified globally by Smithsonian, Scientific American, and National Geographic—proved semaglutide acts as a calorie-restriction mimetic, extending median lifespan by over 12% and slowing cellular aging. 🔗 Nature Study: https://www.nature.com/articles/s41586-026-10940-7 Why this is massive for $LXRX: As partner Novo Nordisk ($NVO) scales blockbusters into foundational healthspan and longevity medicine, the total addressable market explodes. Lexicon’s oral ACSL5 asset LX9851 is built to synergize with semaglutide, supercharging fat loss while protecting lean mass. With $75M already collected from $NVO out of a $1B deal, $LXRX is a direct co-beneficiary of this multi-trillion-dollar paradigm shift! $SPY $BIB $VTRS https://www.nature.com/articles/s41586-026-10940-7 https://www.smithsonianmag.com/smart-news/GLP-1-weight-loss-drugs-can-slow-aging-and-extend-lifespan-mouse-study-suggests-180989452/ https://www.scientificamerican.com/article/glp-1-weight-loss-medication-could-slow-aging-and-extend-lifespan/ https://www.nationalgeographic.com/health/article/glp-1-drugs-aging-longevity
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 3 at 4:10 PM
$LXRX Management's September NYC Conference Blitz is a Major Tell 🗽📈 Lexicon just dropped a three-conference September tour: Citi (Sept 9), Cantor (Sept 10), and H.C. Wainwright (Sept 14). Why it matters: Packing top-tier biotech conferences into a 6-day window right after Labor Day isn't random. It’s a targeted institutional capital-markets blitz right ahead of the Q4 Zynquista T1D NDA resubmission. Between the recent $10M Novo Nordisk milestone for LX9851, Phase 3 HCM progress, and non-opioid pain catalysts, management is teeing up major visibility. Expect fireside Q&A color. Sellers sleeping on this setup are handing shares to smart money! NFA $NVO $VTRS $SPY $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 1 at 5:00 PM
$LXRX Submittal is pending and within expected date range of submittal. Obviously the Oral Pill does not eliminate the Insulin Jab completely. But it **greatly** lowers the occurence of needing to use it for glycemic, sugar control. As the Images coupled with the post indicate. Also of note: There is a $NVO 1 Bil agreement to use $LXRX lx9851 different pathway to weightloss that preserves muscle mass, and eliminates flat face, and other negative effects of artificial GLP1 injected, vs lx9851 that helps the body CREATE it's OWN** natural GLP1 per body usage. Also $LXRX has cardio treatment indications. FDA approved, with new indication approval for HCM in phase 3 topline due early 2027. $SPY $BIB $VTRS
0 · Reply
Latest News on BIB
Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

2026-02-19T19:18:15.000Z - 6 months ago

Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

CRBU CRNX GNOM HRTS REGN VKTX VRTX

macrossluvsrobotech
macrossluvsrobotech Sep. 11 at 4:31 PM
$LXRX Just in 1bil from Novo, puts our share value at: 2.47 ... our cash is .30 cent a share. Meaning, FAIR MARKET VALUE JUST ON NOVO AND CASH? 2.77 a share. NOT COUNTING THE SUBMITTAL=AND EVERYTHING ELSE= I SAID .80 CENTS IN PRIOR POSTS IN INCREMENTAL ROYALTIES... ON TOP OF THIS OBVIOUS VALUATION...I SHOULD HAVE BEEN CLEARER. 445 mil shares divided by 1 bil = 2.47 a share. PLUS .30 cents from our cash. ALONE put's us at 2.77 a share. NOT COUNTING THE MINIMUM .80 CENT ROYALTY MINIMUM VALUE PER SHARE IN THE FUTURE FROM REVENUE SHARE SALES. WHICH EASILY PUTS US AT 3.05 SHARE. $NVO $VTRS $BIB $SPY = ( AI SOFTWARE LAYER FACTOR FOR GENOME 5,000 VAULT, WITH OTHER INDICATIONS AND ONCOLOGY AS AN EXAMPLE, AND MENTIONED )
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 11 at 4:04 PM
$LXRX — count the VALUE/estate, not just the 'ticker'. Novo LX9851 (oral obesity / fat-metabolism pill): up to $1B headline. $75M already in. Rest = milestones (goal payments) + royalties (sales cut). Easy minimum, floor value per share ≈ $0.80/sh. Zynquista T1D (type 1 diabetes): ~1M US adults. No approved *oral* add-on to minimize need 4 daily painful insulin jab. FIRST OF ITS KIND- IN THE U.S. Q4 FDA file (Oct–Dec). Efficacy accepted!!!!!!!!. Gate was DKA (dangerous acid buildup). STENO-1 (Denmark safety study) was that gate. Minimum value in sales per share: ≈ $2.20/sh. SONATA + AAK1 appx minimum value per share ≈ $1.45/sh. SONATA = P3 (late trial) in HCM (thick stiff heart), Q1’27. Camzyos ( another similar brand, inferior ) already banks ~$1B+/yr; no nHCM . AAK1 = pilavapadin, non-opioid for DPNP (diabetic nerve pain). P3 = partner’s check, but could be 1.80-3.80 minimum value per share in royalties. Add: ~$6.80–8.80+ vs ~$2. Not a promise. A ledger. $NVO $VTRS $BIB $SPY
0 · Reply
SniperPro
SniperPro Sep. 10 at 11:30 AM
$LXRX $NVO $VTRS $BIB $SPY 🤑 Amazing presentation!!! 🤑 🚀💪💰 IF YOU’RE LOOKING TO PARTNER, THIS IS ONE TO WATCH. 🤝🔥
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 11:03 PM
$LXRX Citi Webcast Takeaways — Disciplined Execution Over Hype 🧬📊 1. T1D NDA (Zynquista): Targeted for Q4 submission. Exton confirmed the Steno-1 exposure hurdle was hit in late August: "Data is done... preparing it and getting ready to submit." DKA rate came in lower than inTandem and similar to standard of care, meeting FDA's stated risk-benefit criteria. 2. HCM (North Star) Q1 '27: SONATA-HCM over-enrolled past 500 patients across 130+ sites. Broad EF range plus a unique background CMI cohort. Management framed a +3-pt placebo-adjusted KCCQ delta as a commercial home run. 3. Capital Discipline on Pain: Pilavapadin (LX9211) won’t drain cash in a self-funded Phase 3. Presenting new cardiometabolic preclinical data later this year to bundle into an expanded partnership package. 4. Genome 5000 + AI: Evaluating an AI query layer over 30 years of proprietary knockout data (origin of Sota, LX9851, LX9211) to explore untouched oncology/immuno. Pure optionality. $NVO $VTRS $BIB $SPY
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 11:00 PM
$LXRX Citi Fireside Breakdown: Big Catalysts & Major AI Discovery Reveal 🧬🚀 1. T1D NDA Locked for Q4: CEO Exton confirmed the Steno-1 exposure hurdle was officially achieved in late August. "Data is done. Now we just are in the throes of preparing it and getting ready to submit." DKA rate matched standard of care and was below in Tandem. FDA green light ready! 2. HCM (North Star) Q1 '27: SONATA-HCM over-enrolled 500+ pts across 20 countries. Covers broad EF range + first-ever CMI background cohort. Management framed a 3-pt KCCQ delta as a commercial "home run." 3. AAK1 Expansion: Pilavapadin (LX9211) won’t drain cash. Presenting new preclinical data in cardiometabolic indications later this year to maximize partnership value. 4. Genome 5000 + AI: Revealing an AI query engine overlaid on 30 yrs of proprietary knockout mouse data (source of Sota, LX9851, LX9211) to unlock untapped oncology & immunology assets! Execution mode across all fronts. $NVO $VTRS $BIB $LLY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 9:38 PM
$LXRX First Conference of Operation Conference Blitzkrieg ; ) , 3 in a row, or go home!!, prior to Inpefa submission: Ready to be listened to, here, for all interested parties: 39 minutes long. CEO's own words: 'we are very soon to submit INPEFA', ; ) New Data, New Admin, New Regime. It's 2026. Not 2019. This webcast can now be discussed on our board, =NOTE THIS IS THE EXACT SAME DAY THEY participated via Lexicon’s Attendees: The individuals representing Lexicon in the audience and at the networking tables are: Lexicon’s internal Patient Advocacy & Public Policy / Government Affairs leads. While CEO was today at the event link below CITI Back to School Confernece, which you can listen to now below. Retained D.C. healthcare lobbying and policy consultants who manage Lexicon's Capitol Hill outreach. Washington/Hill Presentation will be discussed here- should be very interesting ) https://investors.lexpharma.com/news-events/events $NVO $VTRS $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 7:46 PM
$LXRX Current Price vs. Fair Value: Old Fears vs. 2026 Facts 🧬📊 At ~$2.14, backing out ~$0.30 net cash means the market is already pricing ~$1.84 for the science. The ~$5.40 fair value case doesn't deny this. It argues that $1.84 is being weighed down by old 2019 FDA rejection fears, ignoring the updated 2026 clinical record: • Novo Nordisk ($NVO): Already paid $75M cash. Valuing realistic future milestones and royalties adds ~$0.80/sh. • Type 1 Diabetes (Zynquista): ~$2.25/sh. STENO1 cleared key safety hurdles ahead of the Q4 FDA filing (and the molecule is already FDA-approved as INPEFA). • Core Pipeline: ~$1.45/sh. A Phase 3 heart disease trial fully enrolled (Q1 '27 readout) plus a Phase 3-ready non-opioid pain drug. The Math: $0.30 cash + $0.80 Novo + $2.25 T1D + $1.45 pipeline = ~$4.80–$5.80 baseline fair value (up to $7.20+ as T1D approval odds climb). $2.14 is a seller who cannot wait. $5.40 is a buyer who can. Different patience, different value. $VTRS $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 9 at 3:11 AM
$LXRX The Longevity Supercycle: Why ONE Landmark Nature Study Changes Everything 🧬📈 The scientific consensus just shifted. A foundational September 2026 study published in *Nature*—amplified globally by Smithsonian, Scientific American, and National Geographic—proved semaglutide acts as a calorie-restriction mimetic, extending median lifespan by over 12% and slowing cellular aging. 🔗 Nature Study: https://www.nature.com/articles/s41586-026-10940-7 Why this is massive for $LXRX: As partner Novo Nordisk ($NVO) scales blockbusters into foundational healthspan and longevity medicine, the total addressable market explodes. Lexicon’s oral ACSL5 asset LX9851 is built to synergize with semaglutide, supercharging fat loss while protecting lean mass. With $75M already collected from $NVO out of a $1B deal, $LXRX is a direct co-beneficiary of this multi-trillion-dollar paradigm shift! $SPY $BIB $VTRS https://www.nature.com/articles/s41586-026-10940-7 https://www.smithsonianmag.com/smart-news/GLP-1-weight-loss-drugs-can-slow-aging-and-extend-lifespan-mouse-study-suggests-180989452/ https://www.scientificamerican.com/article/glp-1-weight-loss-medication-could-slow-aging-and-extend-lifespan/ https://www.nationalgeographic.com/health/article/glp-1-drugs-aging-longevity
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 3 at 4:10 PM
$LXRX Management's September NYC Conference Blitz is a Major Tell 🗽📈 Lexicon just dropped a three-conference September tour: Citi (Sept 9), Cantor (Sept 10), and H.C. Wainwright (Sept 14). Why it matters: Packing top-tier biotech conferences into a 6-day window right after Labor Day isn't random. It’s a targeted institutional capital-markets blitz right ahead of the Q4 Zynquista T1D NDA resubmission. Between the recent $10M Novo Nordisk milestone for LX9851, Phase 3 HCM progress, and non-opioid pain catalysts, management is teeing up major visibility. Expect fireside Q&A color. Sellers sleeping on this setup are handing shares to smart money! NFA $NVO $VTRS $SPY $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 1 at 5:00 PM
$LXRX Submittal is pending and within expected date range of submittal. Obviously the Oral Pill does not eliminate the Insulin Jab completely. But it **greatly** lowers the occurence of needing to use it for glycemic, sugar control. As the Images coupled with the post indicate. Also of note: There is a $NVO 1 Bil agreement to use $LXRX lx9851 different pathway to weightloss that preserves muscle mass, and eliminates flat face, and other negative effects of artificial GLP1 injected, vs lx9851 that helps the body CREATE it's OWN** natural GLP1 per body usage. Also $LXRX has cardio treatment indications. FDA approved, with new indication approval for HCM in phase 3 topline due early 2027. $SPY $BIB $VTRS
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 1 at 4:47 PM
$LXRX Obviously the $LXRX Oral Pill does not eliminate the Insulin Jab completely. But it **greatly** lowers the occurence of needing to use it for glycemic, sugar control. As the Images coupled with the post indicate. $SPY $NVO $BIB $VTRS
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 1 at 4:11 PM
$LXRX = No More Painful Jabs for Insulin to glycemic ( Blood Sugar ) Control . THE FIRST ORAL PILL that helps in Type1 Diabetes, glycemic control. No more worrying about getting your glycemic count, 'just right' before or after a meal, fiddling with stress, needles, and back of the napkin calculations. First principles: Value ≈ P(approval) × payoff, and P just rose. STENO1 hit the FDA exposure bar in late August, showing DKA rates matching standard of care and well below inTandem—clearing the historical ~3.5 DKA/100 patient-years gating variable. Q4 NDA resubmission brings the first oral insulin adjunct for T1D glycemic control to ~1M US adults. Bayes prior: Administrations deliver high-salience, kitchen-table health wins into midterms (like the IRA $35 insulin cap in Aug '22). Amid soft jobs and sticky inflation, a non-injectable T1D option is prime political currency. $NVO $BIB $VTRS $SPY https://youtu.be/NPGAZFACUoc?si=N7pwImDrGAxveMWM
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 1 at 3:47 PM
$LXRX $NVO $VRTS $BIB $SPY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Sep. 1 at 3:45 PM
$LXRX dip is the seller’s loss. First principles: Value ≈ P(approval) × payoff, and P just rose. STENO1 hit the FDA exposure bar in late August, showing DKA rates matching standard of care and well below inTandem—clearing the historical ~3.5 DKA/100 patient-years gating variable. Q4 NDA resubmission brings the first oral insulin adjunct for T1D glycemic control to ~1M US adults. Bayes prior: Administrations deliver high-salience, kitchen-table health wins into midterms (like the IRA $35 insulin cap in Aug '22). Amid soft jobs and sticky inflation, a non-injectable T1D option is prime political currency. Sellers just handed shares over while the clock runs toward filing. N/FA. Zynquista refiling overview This short video provides a quick overview of Lexicon's regulatory timeline and plans for refiling Zynquista in type 1 diabetes. $NVO $BIB $VRTS https://youtu.be/NPGAZFACUoc?si=N7pwImDrGAxveMWM
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 31 at 4:56 PM
$LXRX $NVO $VRTS $BIB $LLY $LXRX Viral "China cured diabetes" posts mash TWO separate, early-stage trials into a fake national rollout 'news'. 1️⃣ 2024 Cell Study: Only 1 patient, who was already on heavy anti-rejection drugs from a prior liver transplant. 2️⃣ 2026 Lancet Study (E-islet01): Just 3 patients. Mixed results, requires lifelong immunosuppression, and costs $150K+ per custom surgery with no retail price or approval. REALITY: Boutique experimental surgeries are years away from mass scale. They are NOT products you can buy today. WHY IT MATTERS FOR $LXRX: Complex cell procedures with lifelong drug risks can’t help millions right now. That's why accessible, daily oral treatments like Zynquista remain the urgent, scalable winner for Type 1 Diabetes! 📈 NFA Youtube video From Chinese News Service: CNS : https://youtu.be/FdGvAK9qSf0?si=19AM01nKREMtalp5
0 · Reply
jjon2121
jjon2121 Aug. 31 at 4:44 PM
$LABU $LABD $XBI $BIB $IBB Lilly just announced a 2.9B buyout of Merida. We will see if this 1 announcement has any effect with everything else going on. That isn't to say more won't follow. https://www.biopharmadive.com/news/lilly-merida-acquire-deal-immune-drugs-graves-disease/829152/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 31 at 4:42 PM
$LXRX viral “China cured diabetes” posts mash TWO studies. Not a product. 2024 Cell (Deng/Tianjin): ONE published T1D woman. Off insulin day 75. Already on liver-transplant immuno. 1-year paper. Not this weekend. https://www.cell.com/cell/fulltext/S0092-8674(24)01022-5 2026 Lancet (E-islet01, Shanghai): THREE T1D cases. Pt1 first graft FAILED. Redo + heavy immuno: 54→8 units, not off. Pt2 off insulin >26 mo. Pt3 56→16 units, not off. Needs immuno. No list price. China/US IND only. Not approved. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00423-1/fulltext Boutique transplant ≠ 2026 pill. Does not move Zynquista Q4 2026 file. $NVO $VRTS $BIB $LLY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 31 at 3:49 PM
$LXRX :Why Low-BP Matters 🫀 BP (Blood Pressure) is the force of blood against artery walls (Systolic top number over Diastolic bottom). SBP is Systolic Blood Pressure (the top number when the heart beats). Normally, doctors fear treating fragile heart failure patients with SBP < 110 ( lower than 110) (top number under 110 mmHg) because meds can crash BP ( Blood Pressure ) or cause kidney stress. Lexicon's new trial data solves this. Sotagliflozin achieved an HR 0.56 (Hazard Ratio), meaning patients on the drug had 56% of the adverse events of placebo ( ALMOST HALF!!), vs 100% , 100 minus 56 = a 44% reduction in CV (Cardiovascular)-death/HF ( Heart Failure) events. Physically, it unloads heart fluid via dual SGLT1/2 inhibition without crashing BP or causing kidney injury (zero difference vs placebo). The point: INPEFA is safe and effective when BP ( Blood Pressure) is low! $NVO $VRTS $BIB $LLY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 31 at 2:22 PM
$LXRX 🚨 New ESC 2026 & JACC Data: Addressing the "Recycled Data" FUD on SOLOIST-WHF. Skeptics claim today's PR is just rehashed data. Let's look at the facts: WHAT’S NEW: A newly published subgroup analysis evaluating Sotagliflozin (INPEFA) across baseline Systolic Blood Pressure (SBP) levels: • SBP <110 mmHg (n=201): HR 0.56 (p=0.03) — 44% reduction in CV death & HF events! • SBP ≥110 mmHg: HR 0.69 (p=0.01). • Safety: NO increased risk of hypotension (p=0.34) or acute kidney injury (p=0.69) vs placebo, even down to 100 mmHg baseline SBP. WHY IT MATTERS: In the real world, cardiologists hesitate to prescribe SGLT inhibitors to low-BP, fragile heart failure patients fearing dangerous blood pressure drops or kidney strain. This gives physicians peer-reviewed proof in JACC: Heart Failure that INPEFA is safe and effective in this vulnerable cohort. It directly dismantles a major prescribing hurdle. Solid clinical execution! 📈 PR: https://lexiconpharma.gcs-web.com/news-releases/news-release-details/lexicon-announces-new-post-hoc-soloist-whf-analysis $NVO $VTRS $BIB $LLY
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 30 at 7:30 PM
$CMPS $SNDL $MSOS $BIB New Mexico Launches Medical Psilocybin Producer Permit Applications: “The state is working really hard to operationalize this program as quickly as possible. People are suffering and they want to address that suffering.”
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 28 at 6:40 PM
$LXRX Into Midterms ( Exton and Debbane are playing this perfectly ) Trump admin will want to take credit for being the first ever Administration to provide an oral supplement to ease or greatly reduce, perhaps replace for many, the use of a painful injection, jab of insulin. Watch. Type 1 Diabetes. Gonna Make Type 1 Diabetes Management... Great .....Again. $NVO $VTRS $BIB $LLY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 28 at 2:21 PM
$LXRX LXRX THEY ARE SELLING YOU BOTH ALPHA AND AN INFLATION HEDGE, WAR HEDGE, OIL HEDGE AT A FIRESALE PRICE, BECAUSE THEY CAN'T TAKE THE TIME TO READ THE HCM RESULTS, FROM $CYTK . $CYTK = HCM ( A COMPLETELY DIFFERENT CHEMICAL PATHWAY THAN SOTAGLIFLOZIN) PHASE 3 RESULTS ( TELLS THE HEART TO SLOW DOWN, DUE TO INFLEXIBLE HEART MUSCLE WALL, BRINGING HEART DANGEROUSLY CLOSE TO STOPPING ALL TOGETHER) = BAD VS $LXRX = HCM ( A COMPLETELY DIFFERENT CHEMICAL PATHWAY THAN $CYTK, ) SOTAGLIFLOZIN FROM $LXRX HELPS THE MUSCLE WALL ITSELF BECOME MORE FLEXIBLE AND DOES NOT SLOW DOWN THE HEART ITSELF = GOOD ) PHASE 3 RESULTS = GOOD. $NVO $VRTS $BIB
1 · Reply